Reducing the risk of obesity: Defining the role of weight loss drugs

Pharmacotherapy

Volumn 33, Issue 12, 2013, Pages 1308-1321

  Ling, Hua ^a   Lenz, Thomas L ^b   Burns, Tammy L ^a   Hilleman, Daniel E ^b  

^a CREIGHTON UNIVERSITY CARDIAC CENTER   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF PHARMACY AND HEALTH PROFESSIONS   (United States)

Author keywords

bariatric surgery; diet; exercise; obesity; weight loss drugs

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; AMFEPRAMONE; ANTIOBESITY AGENT; BENZPHETAMINE; DEXFENFLURAMINE; FENFLURAMINE; GLUCOSE; INSULIN; LORCASERIN; PHENDIMETRAZINE; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

BARIATRIC SURGERY; BLOOD PRESSURE; BODY MASS; CONSTIPATION; DIET RESTRICTION; DIET THERAPY; DISEASE CLASSIFICATION; DIZZINESS; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENERGY EXPENDITURE; FATIGUE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; INSOMNIA; INSULIN BLOOD LEVEL; KINESIOTHERAPY; LIFESTYLE MODIFICATION; LIPID ANALYSIS; MORBID OBESITY; MORTALITY; NAUSEA; OBESITY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; TACHYCARDIA; TREATMENT FAILURE; VOMITING; WAIST CIRCUMFERENCE; WEIGHT CONTROL; WEIGHT REDUCTION; XEROSTOMIA;

BARIATRIC SURGERY; DIET; EXERCISE; OBESITY; WEIGHT-LOSS DRUGS;

ANTI-OBESITY AGENTS; BARIATRIC SURGERY; HUMANS; LIFE STYLE; OBESITY; OBESITY, MORBID; PATIENT COMPLIANCE; PREVALENCE; PUBLIC HEALTH; TIME FACTORS; WEIGHT LOSS;

EID: 84897500490     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1277     Document Type: Review

References (77)

1. World Health Organization. Obesity and overweight. Available from http://www.who.int/mediacnetre/factsheets/fs311/index.html. Accessed October 18, 2012.
2. Flegal KM, Carroll MD, Kit BK, Ogden CL,. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012; 307 (5): 491-7.
3. Ogden CL, Carroll MD, Kit BK, Flegal KM,. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. JAMA 2012; 307 (5): 483-90.
4. Morton G, Cummings D, Baskin D, Barsh G, Schwartz M,. Central nervous system control of food intake and body weight. Nature 2006; 443 (7109): 289-95.
5. Müller M, Bosy-Westphal A, Krawczak M,. Genetic studies of common types of obesity: a critique of the current use of phenotypes. Obes Rev 2010; 11 (8): 612-8.
6. Wareham NJ, Young EH, Loos RJF,. Epidemiological study designs to investigate gene-behavior interactions in the context of human obesity. Obesity 2012; 16 (S3): S66-71.
7. Silventoinen K, Rokholm B, Kaprio J, Sørensen T,. The genetic and environmental influences on childhood obesity: a systematic review of twin and adoption studies. Int J Obes 2009; 34 (1): 29-40.
8. Luppino FS, De Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry 2010; 67 (3): 220-9.
9. Sharma AM,. Obesity and mental health-a complicated and complex relation. Can J Psychiatry 2012; 57 (1): 3-4.
10. Gariepy G, Nitka D, Schmitz N,. The association between obesity and anxiety disorders in the population: a systematic review and meta-analysis. Int J Obes 2010; 34 (3): 407-19.
11. National Task Force on the Prevention and Treatment of Obesity. Overweight obesity health risk. Arch Intern Med 2000; 160 (3): 898-904.
12. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH,. The disease burden associated with overweight and obesity. JAMA 1999; 282 (16): 1523-9.
13. Allison DB, Fontaine KR, Manson JE, Stevens J, VanItallie TB,. Annual deaths attributable to obesity in the United States. JAMA 1999; 282 (16): 1530-8.
14. Fontaine KR, Redden DT, Wang CX, Westfall AO, Allison DB,. Years of life lost due to obesity. JAMA 2003; 289 (2): 187-93.
15. Wolf AM,. What is the economic case for treating obesity? Obes Res 2012; 6 (Suppl 1): 2S-7S.
16. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report. Obes Res 1998; 6 (Suppl 2): 51S-209S.
17. National Institutes of Health. The practical guide: identification, evaluation, and treatment of overweight and obesity in adults. NIH Publication No. 00-4084 (2000).
18. Jakicic JM, Clark K, Coleman E, et al. American College of Sports Medicine position stand. Appropriate intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exerc 2001; 33 (12): 2145.
19. US Department of Health and Human Services. Physical activity and health: a report of the Surgeon General. Sudbury, MA: Jones & Bartlett Learning 1996; 278 pp.
20. US Department of Health and Human Services. 2008 physical activity guidelines for Americans. Be active, healthy, and happy (2008). Available from http://www.health.gov/paguidelines/guidelines/default.aspx.
21. Bray GA,. Medications for weight reduction. Med Clin North Am 2011; 95 (5): 989-1008.
22. Bray GA, Ryan DH,. Medical therapy for the patient with obesity. Circulation 2012; 125 (13): 1695-703.
23. Colman E,. Food and Drug Administration's Obesity Drug Guidance Document: a short history. Circulation 2012; 125 (17): 2156-64.
24. Powell AG, Apovian CM, Aronne LJ,. New drug targets for the treatment of obesity. Clin Pharmacol Ther 2011; 90 (1): 40-51.
25. Rothman RB, Baumann MH,. Serotonergic drugs and valvular heart disease. Expert Opin Drug Saf 2009; 8 (3): 317-29.
26. Brenot F, Herve P, Petitpretz P, Parent F, Duroux P, Simonneau G,. Primary pulmonary-hypertension and fenfluramine use. Br Heart J 1993; 70 (6): 537-41.
27. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337 (9): 581-8.
28. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335 (9): 609-16.
29. Yao W, Mu W, Zeifman A, et al. Fenfluramine-induced gene dysregulation in human pulmonary artery smooth muscle and endothelial cells. Pulm Circ 2011; 1 (3): 405-18.
30. McNeely W, Goa KL,. Sibutramine. A review of its contribution to the management of obesity. Drugs 1998; 56 (6): 1093-124.
31. James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010; 363 (10): 905-17.
32. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54 (2): 161-202.
33. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S, Group RI-ES. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365 (9468): 1389-97.
34. Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998; 352 (9123): 167.
35. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L,. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27 (1): 155-61.
36. Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J,. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005; 293 (23): 2873-83.
37. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998; 21 (8): 1288-94.
38. Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2002; 25 (6): 1033-41.
39. Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002; 25 (7): 1123-8.
40. Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000; 160 (9): 1321-6.
41. Zhi J, Mulligan TE, Hauptman JB,. Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients. J Clin Pharmacol 1999; 39 (1): 41-6.
42. Rucker D, Padwal R, Li SK, Curioni C, Lau DC,. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 335 (7631): 1194-9.
43. Hurren KM, Berlie HD,. Lorcaserin: an investigational serotonin 2C agonist for weight loss. Am J Health Syst Pharm 2011; 68 (21): 2029-37.
44. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010; 363 (3): 245-56.
45. Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 2011; 96 (10): 3067-77.
46. O'Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM Study. Obesity (Silver Spring) 2012; 20 (7): 1426-36.
47. Arena Pharmaceuticals. FDA issues complete response letter for lorcaserin new drug application. Available from http://invest.arenapharm.com/ releasedetail.cfm?releaseid=521977. Accessed October 16, 2012.
48. ® (lorcaserin HCl) for chronic weight management in adults who are overweight with a comorbidity or obese. Available from http://invest.arenapharm.com/releasedetail.cfm?ReleaseID=687182. Accessed August 1, 2012.
49. ® (lorcaserin hydrochloride) package insert. Woodcliff Lake, NJ: Eisai Inc.; 2012.
50. ® (phentermine and topiramate extended-release) package insert. Mountain View, CA: VIVUS, Inc.; 2012.
51. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 2012; 20 (2): 330-42.
52. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377 (9774): 1341-52.
53. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012; 95 (2): 297-308.
54. TheHeart.org. Conflicted FDA committee votes against recommending approval of weight loss drug Qnexa. Available from http://www.theheart.org/ article/1099511.do. Accessed August 1, 2012.
55. FDA.gov. FDA approves weight-management drug Qsymia. Avaialble from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312468.htm. Accessed August 1, 2012.
56. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010; 376 (9741): 595-605.
57. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) 2011; 19 (1): 110-20.
58. Theheart.org. FDA declines approval for Contrave diet drug; asks for CVD outcomes studies. Available from http://www.theheart.org/article/1179441.do. Accessed August 1, 2012.
59. Clinicaltrials Gov. Cardiovascular outcomes study of naltrexone SR/bupropion sr in overweight and obese subjects with cardiovascular risk factors. Available from http://clinicaltrials.gov/ct2/show/NCT01601704. Accessed August 1, 2012.
60. ® (metformin hydrochloride) package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2009.
61. Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, et al. Ten-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009; 374 (9702): 1677-86.
62. Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care 2012; 35 (4): 731-7.
63. Seifarth C, Schehler B, Schneider HJ,. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Exp Clin Endocrinol Diabetes 2013; 121 (01): 27-31.
64. Fontbonne A, Diouf I, Baccara-Dinet M, Eschwege E, Charles MA,. Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial. Diabetes Metab 2009; 35 (5): 385-91.
65. ® (zonisamide) package insert. Teaneck, NJ: Eisai Inc.; 2004.
66. Gadde KM, Franciscy DM, Wagner HR 2nd, Krishnan KR,. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 2003; 289 (14): 1820-5.
67. Gadde KM, Kopping MF, Wagner HR, Yonish GM, Allison DB, Bray GA,. Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial. Arch Intern Med 2012; 172 (20): 1557-64.
68. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28 (5): 1083-91.
69. Buse JB, Henry RR, Han J, et al. Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27 (11): 2628-35.
70. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD,. Effects of exenatide (Exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28 (5): 1092-100.
71. Buse JB, Klonoff DC, Nielsen LL, et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 2007; 29 (1): 139-53.
72. Rosenstock J, Klaff LJ, Schwartz S, et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care 2010; 33 (6): 1173-5.
73. NIH Conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. Ann Intern Med 1991; 115 (12): 956-61.
74. Smith BR, Schauer P, Nguyen NT,. Surgical approaches to the treatment of obesity: bariatric surgery. Med Clin North Am 2011; 95 (5): 1009-30.
75. Christou NV, MacLean LD,. Effect of bariatric surgery on long-term mortality. Adv Surg 2005; 39: 165-79.
76. Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357 (8): 741-52.
77. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292 (14): 1724-37.